1  -0.01 (-0.99%)		05-03 16:00
Open: 1.07 High: 1.075 Volume: 11,016		Pre. Close: 1.01 Low: 1 Market Cap: 37(M)

Short term
Mid term
Targets	6-month :	1.38	1-year :	1.53
Resists	First :	1.18	Second :	1.3
Pivot price	1.05
Supports	First :	0.99	Second :	0.82
MAs	MA(5) :	1.04	MA(20) :	1.07
	MA(100) :	1.13	MA(250) :	4.95
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	19.1	D(3) :	24.7
RSI	RSI(14): 42.6
52-week	High :	33	Low :	0.86

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ESLA ] has closed above bottom band by 5.5%. Bollinger Bands are 57.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.08 - 1.08	1.08 - 1.09
Low:	0.99 - 0.99	0.99 - 1
Close:	0.99 - 1	1 - 1.01

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Wed, 10 Apr 2024
Estrella Immunopharma Unveils Updated Investor Presentation - TipRanks.com - TipRanks

Wed, 31 Jan 2024
Estrella Immunopharma Approves $1 Million Stock Buyback Program - TipRanks.com - TipRanks

Thu, 18 Jan 2024
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances - InvestorPlace

Fri, 12 Jan 2024
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace

Fri, 08 Dec 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace

Fri, 29 Sep 2023
TradeUP Acquisition Corp. and Estrella Biopharma to Combine - citybiz

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	37 (M)
Shares Float	11 (M)
Held by Insiders	70.5 (%)
Held by Institutions	0.3 (%)
Shares Short	8 (K)
Shares Short P.Month	41 (K)

EPS	-0.21
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.25
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-83.7 %
Return on Equity (ttm)	-220.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-5
PEG Ratio	0
Price to Book value	3.84
Price to Sales	0
Price to Cash Flow	-3.14

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.